Merck Resolves Over 1,000 Zostavax Lawsuits Following Plaintiff Dismissals
Rahway, New Jersey — Merck & Co., a leading pharmaceutical company, has reached a significant legal milestone by resolving over a thousand lawsuits connected to its shingles vaccine, Zostavax. The cases were concluded following the plaintiffs’ decision to request dismissals, thus eliminating a batch of longstanding legal grievances against the drugmaker. Zostavax, designed to prevent shingles in older adults, was approved by the U.S. Food and Drug Administration in 2006. Marketed until its production ceased in 2020, it was the only shingles vaccine available in the U.S. for a decade before competitors like Shingrix emerged. … Read more